2024/07/17 16:55:00 | |
---|---|
Price | |
934.15 DKK | |
Difference | -3.61% (-35.00) |
ISIN | DK0062498333 |
Symbol | NOVO B |
Exchange | London Stock Exchange European Trade Reporting |
Currency | DKK |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 410,869 EUR |
Benchmark | OMX COPENHAGEN 20 |
Bid (Bid size) | 915.50 DKK (1,000) |
Ask (Ask size) | 952.80 DKK (1,000) |
Open | 952.85 DKK |
High | 952.00 DKK |
Low | 919.00 DKK |
Close (prev. day) | 969.15 DKK |
VWAP | 927.954199 DKK |
Volume (pcs) | 32,908 |
Trading volume | 24,920,210.01 |
Number of trades | 142 |
Last size | - |
Related Futures | 30 |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/17 16:55:00 | |
---|---|
Price | |
934.15 DKK | |
Difference | -3.61% (-35.00) |
ISIN | DK0062498333 |
Symbol | NOVO B |
Exchange | London Stock Exchange European Trade Reporting |
Currency | DKK |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 410,869 EUR |
Benchmark | OMX COPENHAGEN 20 |
Bid (Bid size) | 915.50 DKK (1,000) |
Ask (Ask size) | 952.80 DKK (1,000) |
Open | 952.85 DKK |
High | 952.00 DKK |
Low | 919.00 DKK |
Close (prev. day) | 969.15 DKK |
VWAP | 927.954199 DKK |
Volume (pcs) | 32,908 |
Trading volume | 24,920,210.01 |
Number of trades | 142 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | +26.24% | +72.57% | +233.58% |
Perf (abs.) | +191.00 | +386.45 | +643.50 |
Beta | 1.36 | 1.43 | 1.27 |
Volatility | 28.66 | 32.06 | 30.08 |
Ø price 5 days | Ø volume 5 days (pcs.) | 960.70 DKK (32,438) |
Ø price 30 days | Ø volume 30 days (pcs.) | 979.67 DKK (49,939) |
Ø price 100 days | Ø volume 100 days (pcs.) | 915.90 DKK (50,038) |
Ø price 250 days | Ø volume 250 days (pcs.) | 778.53 DKK (53,937) |
YTD High | date | 1,031.00 DKK (2024/06/26) |
YTD Low | date | 689.70 DKK (2024/01/02) |
52 Weeks High | date | 1,031.00 DKK (2024/06/26) |
52 Weeks Low | date | 527.65 DKK (2023/07/28) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/07/17 | 17:35 | 123.82 EUR | 13.76 | 2,317 |
Vienna Stock Exchange | 2024/07/17 | 17:32 | 123.58 EUR | 0.07 | 23 |
Tradegate | 2024/07/17 | 22:26 | 123.86 EUR | 16.04 | 1,329 |
Stuttgart | 2024/07/17 | 21:48 | 123.32 EUR | 0.54 | 51 |
Nasdaq Copenhagen | 2024/07/17 | 17:20 | 919.00 DKK | 3,279.57 | 48,199 |
Munich | 2024/07/17 | 17:36 | 123.86 EUR | 0.02 | 4 |
London Stock Exchange European Trade Reporting | 2024/07/17 | 16:55 | 934.15 DKK | 24.92 | 142 |
Hanover | 2024/07/17 | 15:34 | 124.12 EUR | 0.01 | 2 |
Hamburg | 2024/07/17 | 18:41 | 123.46 EUR | 0.01 | 4 |
Frankfurt | 2024/07/17 | 21:36 | 124.12 EUR | 1.48 | 144 |
FINRA other OTC Issues | 2024/07/17 | 21:59 | 134.25 USD | 0.26 | 44 |
Duesseldorf | 2024/07/17 | 20:25 | 124.70 EUR | 0.03 | 13 |
Berlin | 2024/07/17 | 09:56 | 126.74 EUR | 0.01 | 3 |
NOVO NORDISK A/S |
- - |
Novo Allé 1 - 2880 Bagsværd |
Telefon: +45-44-44-88-88 |
Fax: + |
E-mail: - |
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark. |
Lars Fruergaard Jørgensen | Chairman of Managing Board |
Camilla Sylvest | Member of Executive Committee |
David Moore | Member of Executive Committee |
Doug Langa | Member of Executive Committee |
Henrik Wulff | Member of Executive Committee |
Karsten Munk Knudsen | Member of Executive Committee |
Ludovic Helfgott | Member of Executive Committee |
Marcus Schindler | Member of Executive Committee |
Martin Holst Lange | Member of Executive Committee |
Maziar Mike Doustdar | Member of Executive Committee |
Tania Sabroe | Member of Executive Committee |
Helge Lund | Chairman of Supervisory Board |
Martin MacKay | Member of Supervisory Board |
Sylvie Grégoire | Member of Supervisory Board |
Andreas Fibig | Member of Supervisory Board |
Christina Law | Member of Supervisory Board |
Elisabeth Christensen | Member of Supervisory Board |
Henrik Poulsen | Member of Supervisory Board |
Kasim Kutay | Member of Supervisory Board |
Laurence Debroux | Member of Supervisory Board |
Liselotte Hyveled | Member of Supervisory Board |
Mette Bøjer Jensen | Member of Supervisory Board |
Thomas Rantzau | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer